Rezolute Dirección

Dirección controles de criterios 3/4

El CEO de Rezolute's es Nevan Elam , nombrado en Jan 2013, tiene una permanencia de 11.25 años. compensación anual total es $973.65K, compuesta por 54.9% salario y 45.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.019% de las acciones de la empresa, por valor de $27.67K. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 3.6 años, respectivamente.

Información clave

Nevan Elam

Chief Executive Officer (CEO)

US$973.6k

Compensación total

Porcentaje del salario del CEO	54.9%
Permanencia del CEO	11.3yrs
Participación del CEO	0.02%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Nevan Elam en comparación con los beneficios de Rezolute?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$57m
Sep 30 2023	n/a	n/a	-US$56m
Jun 30 2023	US$974k	US$534k	-US$52m
Mar 31 2023	n/a	n/a	-US$48m
Dec 31 2022	n/a	n/a	-US$44m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	US$8m	US$515k	-US$41m
Mar 31 2022	n/a	n/a	-US$38m
Dec 31 2021	n/a	n/a	-US$31m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	US$5m	US$496k	-US$21m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	n/a	n/a	-US$19m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	US$4m	US$490k	-US$20m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	n/a	n/a	-US$37m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	US$732k	US$453k	-US$33m
Mar 31 2019	n/a	n/a	-US$42m
Dec 31 2018	n/a	n/a	-US$25m
Sep 30 2018	n/a	n/a	-US$27m
Jun 30 2018	US$468k	US$450k	-US$30m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	n/a	n/a	-US$27m
Sep 30 2017	n/a	n/a	-US$27m
Jun 30 2017	US$3m	US$450k	-US$24m

Compensación vs. Mercado: La compensación total de Nevan($USD973.65K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Nevan ha sido consistente con los resultados de la empresa en el último año.

CEO

Nevan Elam (56 yo)

11.3yrs

Permanencia

US$973,646

Compensación

Mr. Nevan Charles Elam, J.D., is a Founder of Rezolute, Inc. and serves as its Chief Executive Officer and Director at since January 31, 2013. Mr. Elam serves as Acting Chairman of the Board at Rezolute, I...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nevan Elam	Founder	11.3yrs	US$973.65k	0.019% $ 20.9k
Brian Roberts	Chief Medical Officer	4.3yrs	US$738.86k	0.13% $ 143.7k
Daron Evans	Chief Financial Officer	less than a year	sin datos	0.40% $ 428.5k
Davelyn Hood	Director and Head of Scientific & Patient Affairs	2.9yrs	sin datos	sin datos
Michael Deperro	Senior VP & Head of Corporate Development	1.3yrs	sin datos	sin datos
Michael Covarrubias	Senior VP & Head of Program & Portfolio Management	3.1yrs	sin datos	sin datos
Chris Milks	VP & Head of Finance	no data	sin datos	sin datos
Raj Agrawal	VP & Head of Ophthalmological Clinical Development	no data	sin datos	sin datos
Robyn Sweinhart	VP & Head of Quality	no data	sin datos	sin datos
Erin O'Boyle	Senior VP & Head of Clinical Operations	no data	sin datos	sin datos
Susan Stewart	Chief Regulatory Officer	1.5yrs	sin datos	sin datos
Gopal Saha	Senior Vice President of Global Clinical Development	less than a year	sin datos	sin datos

2.2yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RZLT se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nevan Elam	Founder	11.3yrs	US$973.65k	0.019% $ 20.9k
Jerrold Olefsky	Member of the Scientific Advisory Board	10yrs	sin datos	sin datos
Gilbert Labrucherie	Independent Director	4.4yrs	US$69.00k	0.13% $ 143.6k
Philippe Fauchet	Independent Director	3.6yrs	US$66.00k	0% $ 0
Young-Jin Kim	Director	5.2yrs	US$33.75k	0.29% $ 309.4k
Quan Dong Nguyen	Member of the Scientific Advisory Board	2.9yrs	sin datos	sin datos
Nerissa Kreher	Independent Director	3.1yrs	US$62.00k	0% $ 0
Robert B. Bhisitkul	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Wladimir Hogenhuis	Independent Director	3.1yrs	US$64.00k	0.081% $ 87.6k
Adrian Vella	Member of the Scientific Advisory Board	2.6yrs	sin datos	sin datos
Alvin Schmaier	Member of the Scientific Advisory Board	no data	sin datos	sin datos

3.6yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de RZLT se considera experimentada (3.6 años de antigüedad promedio).

Rezolute Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Chief Financial Officer recently bought US$67k worth of stock

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

High number of new and inexperienced directors

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Recent updates

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50

Rezolute, Inc. Announces CFO Changes

Rezolute, Inc. announced that it expects to receive $40.92 million in funding from BVF Partners LP, Citadel Advisors LLC, and other investors

Rezolute, Inc. announced delayed annual 10-K filing

Rezolute Announces Publication of Rz402 Data in Diabetic Macular Edema (Dme) in Investigative Ophthalmology & Visual Science

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad